FDA OK's Purdue's new abuse-deterrent oxycodone Targiniq ER
This article was originally published in Scrip
Executive Summary
Purdue Pharma won another approval of an abuse-deterrent oxycodone drug, gaining the FDA's blessing on 23 July to market Targiniq ER (oxycodone/naloxone), an extended-release/long-acting (ER/LA) opioid analgesic.